←
AviadoBio428 posts
AviadoBio avatar

AviadoBio

@AviadoBio

Translating groundbreaking science and precision delivery into life-changing medicines for people living with devastating neurodegenerative diseases.

◷ Joined July 2021▧ 348 Photos and videos
AviadoBio avatar
AviadoBio@AviadoBio·Nov 13

What makes a successful partnership? Our COO​,​ Graeme Fielder, PhD, shares ​his perspective & will explore this at @CooleyLLP's Breakthrough Bootcamp on Nov. 17 at 1:35 p.m. GMT in “The Art of In-Licensing” panel. Attending​ #LondonLifeSciencesWeek​​? Connect with Graeme.

1:04
AviadoBio avatar
AviadoBio@AviadoBio·Nov 13

Our CEO, Lisa Deschamps, joins Cell & Gene Live on Sunday for the “Scaling genetic medicines from payload to patient” panel alongside CGT leaders from across the industry. Don’t miss this insightful session if you’re in London for #Jefferies: cellandgene.live

Post attachment
AviadoBio avatar
AviadoBio@AviadoBio·Nov 11

We’re looking forward to joining leaders in the field at Cell 2026 & sharing what’s ahead for AviadoBio. Our team will be onsite to connect with researchers, developers & partners advancing gene therapy innovation. If you’re attending, let’s find time to meet. @NextGenBiomedOG

Post attachment
AviadoBio avatar
AviadoBio@AviadoBio·Nov 9

This #NationalSTEMDay, we celebrate the innovators whose curiosity and dedication advance scientific discovery. At AviadoBio, we’re proud to be part of the scientific community exploring new frontiers in gene therapy. Together, we’re turning possibilities into progress. #STEM

Post attachment
AviadoBio avatar
AviadoBio@AviadoBio·Nov 6

Advanced therapies can better reach patients on the market if they can be made at scale and at a sustainable cost. On Nov. 10, our CDO Alex Bloom, PhD, moderates a #BIOEurope panel on manufacturing cell and gene therapies, mRNA and other next-gen modalities. In Cologne? DM us.

Post attachment
AviadoBio avatar
AviadoBio@AviadoBio·Nov 5

Progress in PSP & CBD depends on collaboration among researchers, clinicians & patient communities, and #Neuro2026 brings all three together in London. Our team is attending the PSP and CBD International Research Symposium to explore advancing research. @CurePSP

Post attachment
AviadoBio avatar
AviadoBio@AviadoBio·Oct 26

Treatment options for Alzheimer's disease and other tauopathies remain limited — the need for new therapies is urgent. We're advancing AVB-406, our investigational gene therapy for Alzheimer's and other tauopathies, built on our vMiX™ platform. #AlzheimersDisease #GeneTherapy

Post attachment
AviadoBio avatar
AviadoBio@AviadoBio·Oct 14

We connected with the ophthalmology community at #AAO2026 to explore the potential of optogenetics for inherited retinal diseases (IRDs). These conversations are an important part of the journey as we advance our investigational gene therapy, AVB-307, for RP & other IRDs.

Post attachment
AviadoBio avatar
AviadoBio@AviadoBio·Oct 12

Last week, we connected with researchers, clinicians & families at #ISFTD2026 who are driving the field forward & had the opportunity to share additional Phase 1/2 ASPIRE-FTD data for our investigational gene therapy, AVB-101. The momentum is strong. We’re ready for what’s next.

Post attachment